Thông tin cho nhân viên y tế

Thuốc mới và thông tin từ Drugs.com

Thông tin từ The Pharma Letter

  • Japanese ophthalmology major Santen Pharmaceutical has licensed the Asia rights to Chinese biopharma RemeGen’s VEGF/FGF-targeted eye drug RC28-E, a PIII therapy for wet age-related macular degeneration (wAMD), in a deal worth up to 1.3 billion renminbi ($181 million).
  • Elix has announced that fellow Japanese firm Kyorin Pharmaceutical has adopted Elix Discovery, its proprietary AI-powered drug discovery platform.
  • The US Food and Drug Administration (FDA) has lifted the clinical hold on Rocket Pharmaceuticals’ pivotal Phase II trial of RP-A501 for the treatment of Danon disease, the company revealed today, sending its shares up a robust 22% to $3.56 in early trading.
  • Swiss pharma company Idorsia announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the management of systemic hypertension, published by the American College of Cardiology (ACC) and the American Heart Association (AHA) Joint Committee.
  • VantAI, a specialist in generative AI for proximity drug discovery, and Halda Therapeutics, a company focused on regulated induced proximity targeting chimeras (RIPTAC), have agreed a strategic research collaboration worth more than $1 billion in total potential value, inclusive of upfront and milestone payments across multiple targets.
  • AlzeCure Pharma, a Swedish pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, has appointed Cecilia Wadell as head of development.

Thông tin từ BioPharmaDive

Thông tin từ STAT News

Thông tin từ Nature Review Drug Discovery